Target Name: Transfer RNA methionine (anticodon CAU)
NCBI ID: G100126484
Review Report on Transfer RNA methionine (anticodon CAU) Target / Biomarker Content of Review Report on Transfer RNA methionine (anticodon CAU) Target / Biomarker
Transfer RNA methionine (anticodon CAU)
Other Name(s): TRNAM-CAU

The Importance of Transfer RNA Methionine in Protein Synthesis

Transfer RNA (tRNA) methionine plays a vital role in protein synthesis, making it a crucial component for normal cellular functions. In recent years, the significance of tRNA methionine has expanded from a mere biomarker to a potential drug target. This article explores the importance of tRNA methionine in protein synthesis and its potential as a drug target or biomarker for various diseases and conditions.

The Role of tRNA Methionine

tRNA methionine is responsible for carrying the amino acid methionine to the ribosomes during the translation process, where it is incorporated into polypeptide chains to form proteins. The initiation of protein synthesis often begins with methionine, making tRNA methionine essential for accurate and efficient translation.

During translation initiation, a specialized tRNA molecule, known as the initiator tRNA or tRNAiMet, recognizes the start codon on messenger RNA (mRNA). This binding of tRNAiMet to the start codon ensures the correct positioning of the mRNA on the ribosome and facilitates the assembly of the translation machinery.

Furthermore, tRNA methionine also prevents premature translation termination by serving as a decoy for release factors, which typically signal the termination of translation. By binding to release factors, tRNA methionine ensures that translation terminates only at the appropriate stop codons, preventing erroneous or incomplete protein synthesis.

tRNA Methionine as a Drug Target

Given its essential role in protein synthesis, disrupting tRNA methionine function can have significant implications for cell growth and viability. Consequently, targeting tRNA methionine has emerged as a promising strategy for therapeutic intervention in various diseases.

One potential drug target is the enzymes involved in the modification of tRNA methionine. Several enzymes, such as tRNA methyltransferases, are responsible for modifying specific nucleotides on tRNA molecules, including tRNA methionine. Disrupting these enzymes' activity can lead to aberrant tRNA methionine function, impairing protein synthesis, and ultimately impacting cellular processes.

For example, recent studies have shown that manipulating tRNA methylation enzymes can affect the translation of specific mRNAs, particularly those involved in cancer progression. Targeting these enzymes offers a potential avenue for the development of novel anticancer therapies, as altering tRNA methylation can selectively inhibit the translation of cancer-related genes, thereby impeding tumor growth.

Diagnostic Potential of tRNA Methionine

In addition to its role as a drug target, tRNA methionine has also garnered attention as a potential biomarker for various diseases. Abnormalities in tRNA methionine levels or modifications have been associated with several conditions, providing valuable diagnostic information.

For instance, studies have demonstrated altered tRNA methylation patterns in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. These modifications are believed to contribute to the misregulation of protein synthesis and the subsequent accumulation of toxic protein aggregates implicated in disease pathology. Harnessing the diagnostic potential of tRNA methionine modifications may aid in early disease detection and monitoring disease progression.

Furthermore, emerging evidence suggests that tRNA methionine modifications can be indicators of drug response and therapeutic efficacy. By monitoring changes in tRNA methylation patterns, researchers can potentially predict patients' response to specific medications, allowing for personalized treatment regimens and minimizing adverse effects.


Transfer RNA methionine's role in protein synthesis is undeniably crucial for normal cellular functions. Its involvement in accurate translation initiation and termination makes it an attractive target for therapeutic intervention, especially in diseases such as cancer. Additionally, tRNA methylation patterns hold promise as valuable biomarkers for diagnosing and monitoring various diseases.

With further research and advancements in molecular biology techniques, the understanding of tRNA methionine's significance in health and disease is likely to expand. Harnessing this understanding may open doors to novel drug targets, personalized medicine approaches, and improved diagnostics, ultimately benefiting patient care and treatment outcomes.

Protein Name: Transfer RNA Methionine (anticodon CAU)

The "Transfer RNA methionine (anticodon CAU) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Transfer RNA methionine (anticodon CAU) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

Transforming growth factor | Transforming growth factor (TGF)-beta receptor | Transforming growth factor beta | Transglutaminase | Transient Receptor Potential Cation Channel (TRP) | Transient receptor potential cation channel subfamily V | Translation initiation factor IF-2-like, transcript variant X1 | Translocase of inner mitochondrial membrane 23 homolog B (yeast), transcript variant X1 | Translocon-associated protein (TRAP) complex | Transmembrane protein FLJ37396 | TRAP1 | TRAPP complex | TRAPPC1 | TRAPPC10 | TRAPPC11 | TRAPPC12 | TRAPPC13 | TRAPPC14 | TRAPPC2 | TRAPPC2L | TRAPPC3 | TRAPPC3L | TRAPPC4 | TRAPPC5 | TRAPPC6A | TRAPPC6B | TRAPPC8 | TRAPPC9 | TRARG1 | TRAT1 | TRAV1-2 | TRAV10 | TRAV11 | TRAV12-1 | TRAV12-2 | TRAV13-2 | TRAV14DV4 | TRAV19 | TRAV2 | TRAV20 | TRAV21 | TRAV22 | TRAV24 | TRAV25 | TRAV26-1 | TRAV26-2 | TRAV27 | TRAV3 | TRAV34 | TRAV38-2DV8 | TRAV39 | TRAV4 | TRAV41 | TRAV8-1 | TRAV8-2 | TRAV8-3 | TRAV8-4 | TRAV8-6 | TRAV9-1 | TRBC1 | TRBC2 | TRBD1 | TRBD2 | TRBJ1-1 | TRBJ1-2 | TRBJ1-3 | TRBJ1-4 | TRBJ1-5 | TRBJ1-6 | TRBJ2-1 | TRBJ2-2 | TRBJ2-2P | TRBJ2-3 | TRBJ2-4 | TRBJ2-5 | TRBJ2-6 | TRBJ2-7 | TRBV10-1 | TRBV10-2 | TRBV10-3 | TRBV11-1 | TRBV11-2 | TRBV11-3 | TRBV12-3 | TRBV12-4 | TRBV12-5 | TRBV13 | TRBV14 | TRBV15 | TRBV16 | TRBV17 | TRBV18 | TRBV19 | TRBV2 | TRBV20-1 | TRBV21-1 | TRBV21OR9-2 | TRBV22-1 | TRBV23-1 | TRBV24-1